Key facts
- Metri.Bio’s last known valuation is $14.0M (Dec 2025).
- It has raised $5.0M; the latest was Seed Round ($5.0M) in Dec 2025.
- Notable investors include Pillar VC, Navec Investments, Pace Ventures, Slocum Management.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Metri.Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Metri.Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Metri.Bio
Operator of a biotechnology company intended to pioneer first-in-class therapeutics for endometrial disease. The company offers drug development focused specifically on endometrial disorders, enabling customers to access novel treatment options that address unmet medical needs, improve quality of life and advance women's health through targeted, science-driven therapeutics.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2025
- Website
- metri.bio/
- Ownership
- Privately Held (backing)
Metri.Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Metri.Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Metri.Bio in its N-PORT filings yet. We sweep new filings monthly.